Arcoxia ® 90 mg (28 film-coated tablets)

  • $50.80
Out Of Stock
Sku: 368bc817ff15
The instruction for medical use

of Arcoxia® medicine

the Trade name of Arcoxia®

the International unlicensed name


the Dosage form of the Tablet, film coated, 60 mg, 90 mg or 120 mg


One tablet contains

active agent – etorikoksib 60 mg, 90 mg or 120 mg,

excipients: Calcium dihydrophosphate anhydrous, cellulose microcrystalline, sodium of a kroskarmelloz, magnesium stearate,

structure of a film cover: Opadray II Green 39K11520 (lactoses monohydrate – 35%, gipromelloza-33%, the titan % E171-16.6 dioxide, triacetin – 8.0%,

indigokarminovy E132 varnish - 5.4%, gland (III) oxide of yellow 172 - 1.9%), (for 60 mg), Opadray II White 39K18305 (lactoses monohydrate – 35%, gipromelloza-33%,

the titan % E171-24.0 dioxide, triacetin – 8.0%), (for 90 mg), Opadray II Green 39K11529 (lactoses monohydrate – 35%, gipromelloza-33%, the titan % E171-21.6 dioxide, triacetin – 8.0%, indigokarminovy E132 varnish - 1.6%, gland (III) oxide of yellow 172 - 0.9%), (for 120 mg), wax of karnaubskiya.


Dosage of 60 mg:

Tablets of a yablokovidny form, biconvex, film coated green color, with stamping of ARCOXIA 60 on one party, and with stamping 200 on other party.

Dosage of 90 mg:

Tablets of a yablokovidny form, biconvex, film coated white color, with stamping of ARCOXIA 90 on one party, and with stamping 202 on other party.

Dosage of 120 mg:

Tablets of a yablokovidny form, biconvex, film coated light green color, with stamping of ARCOXIA 120 on one party, and with stamping 204 on other party.

Pharmacotherapeutic group

Non-steroidal anti-inflammatory drugs. Koksiba.

The code of automatic telephone exchange M01AH05

the Pharmacological

Pharmacokinetics Quickly properties is soaked up at intake. The bioavailability at intake is about 100%. At use of drug for adults on an empty stomach in a dose of 120 mg the maximum concentration (Cmax) - 3.6 mkg/ml, time of achievement of the maximum concentration (TCmax) in blood plasma - 1 h after reception. Average geometrical AUC0-24ch made 37.8 mkg x h/ml. The pharmacokinetics of an etorikoksib within therapeutic doses has linear character.

Meal has no significant effect on expressiveness and speed of absorption of an etorikoksib in a dose of 120 mg. At the same time, there is a decrease in Cmax values by 36% and increase in TCmax at 2 h.

Communication with proteins of plasma at administration of drug exceeds 92%. The volume of distribution (Vdss) in an equilibrium state is about 120 l. The Etorikoksib gets through a placental and blood-brain barrier.

6-hydroxymethyl-etorikoksiba is intensively metabolized in a liver, with participation of an isoenzyme of P450(CYP) cytochrome and education.

5 metabolites of an etorikoksib, the main - 6-hydroxymethyl-etorikoksib and its derivative – 6-carboxy-acetyl-etorikoksib are revealed. The main metabolites do not influence TsOG-1 and are absolutely inactive or maloaktivna concerning TsOG-2.

Through kidneys 70% of drug are removed, 20% - through intestines, mainly in the form of metabolites. Less than 2% are revealed in not changed look.

Equilibrium concentration of drug is reached at daily reception of 120 mg of drug in 7 days, with cumulation coefficient about 2 that there correspond to elimination half-life about 22 h. The plasma clearance is about 50 ml/min.

Liver diseases

At patients with insignificant abnormal liver functions (5-6 points on Child-Pugh scale) single dose of an etorikoksib in a dose of 60 mg/days was followed by increase by 16% of an indicator of AUC in comparison with healthy faces.

The patients with a moderate abnormal liver function (7-9 points on Child-Pugh scale) taking the drug in a dose of 60 mg every other day had the same AUC value, as at the healthy faces taking the drug daily in the same dose.

Data of clinical and pharmacokinetic trials at patients with a heavy abnormal liver function (more than 9 points on Child-Pugh scale) are absent.

Use for children

In comparative pharmacokinetic researches comparable data at use of an etorikoksib in group of teenagers (from 12 to 17 years) are obtained with a body weight of 40-60 kg in a dose of 60 mg/days, in a similar age group and weighing more than 60 kg - 90 mg/days, and also adults at reception have 90 mg/days.

The pharmacodynamics

of Arcoxia® is selection TsOG-2 inhibitor, in therapeutic concentration blocks formation of prostaglandins and possesses anti-inflammatory, analgeziruyushchy and febrifugal action. Selection oppression of TsOG-2 the drug Arcoxia® is followed by reduction of expressiveness of the clinical symptoms connected with inflammatory process, at the same time is absent influence on function of thrombocytes and a mucous membrane of digestive tract. Аркоксиа® has dose-dependent effect of inhibition of TsOG-2, without influencing TsOG-1 at use of a daily dose up to 150 mg. Drug does not affect production of prostaglandins in a mucous membrane of a stomach and a bleeding time. In the conducted researches the decrease in level of the arachidonic acid and aggregation of thrombocytes caused by collagen was not observed.


- an osteoarthrosis

- a pseudorheumatism

- an ankylosing spondylitis

- gouty arthritis

- primary dysmenorrhea

Inside, irrespective of meal, washing down the Route of administration and doses with a small amount of water.

An osteoarthrosis

the Recommended dose makes 60 mg once a day.

A pseudorheumatism and an ankylosing spondylitis

the Recommended dose makes 90 mg once a day.

Gouty arthritis

the dose Recommended in an acute period makes 120 mg once a day.

Duration of use of drug in a dose of 120 mg is no more than 8 days.

It is necessary to use a minimal effective dose minimum possible short course.

The average therapeutic dose at a pain syndrome makes once 60 mg a day.

Side effects


- an eructation, dryness in a mouth, nausea, vomiting, diarrhea, dyspepsia, epigastric

pain, a meteorism, an abdominal distension, strengthening of a vermicular movement, a constipation,

- gastritis, an ulcer of a mucous membrane of a stomach or a

12-perstny gut, a syndrome of the angry intestines, an esophagitis, ulcers

of a mucous membrane of an oral cavity

- a headache, dizziness, weakness, disturbance of taste, drowsiness,

sleep disorders, disturbance of sensitivity, including.

paresthesias / hyperesthesias, alarm, depression, disturbance of ability to

concentration of attention

- heartbeat, increase in the ABP, feeling of inflows

- disturbance of cerebral circulation, fibrillation of auricles, stagnant

heart failure, nonspecific changes the ECG,

a myocardial infarction

- cough, short wind, nasal bleeding

- ecchymomas, puffiness of the person, a skin itching, rash

- peripheral hypostases, change of appetite, increase in body weight

- increase in hepatic transaminases, increase in nitrogen in blood and urine,

increase in activity of a kreatinfosfokinaza, decrease in a hematocrit,

decrease in hemoglobin, a hyperpotassemia, a leukopenia, thrombocytopenia,

increase in creatinine of serum, increase in uric acid

Is rare

- a gastroenteritis, ulcers of the digestive tract (DT) with bleeding

or perforation

- hepatitis

- hallucinations, confusion of consciousness

- illegibility of sight, conjunctivitis, sonitus, vertigo

- a proteinuria

- a renal failure, is usually reversible at drug withdrawal

- anaphylactic/anaphylactoid reactions, including the profound

lowering of arterial pressure and shock

- hypertensive crisis

- a bronchospasm

- a small tortoiseshell, Stephens-Johnson's syndrome, a Lyell's disease

- infections of an urinary path

- muscular spasms, arthralgias, myalgias

- upper respiratory tract infections, a grippopodobny syndrome,

thorax pains

- increase in sodium in

Contraindication blood serum

- hypersensitivity to any component of drug

- a full or incomplete combination of bronchial asthma,

the nose recuring a polypose or near-nasal bosoms and intolerance

of acetylsalicylic acid and other NPVP

- erosive and ulcer changes mucous a stomach or a 12-perstny gut,

active gastrointestinal bleeding, cerebrovascular or other


- inflammatory bowel diseases (Crohn's disease, nonspecific

ulcer colitis) in an aggravation phase

- hemophilia and other disturbances of blood clotting

- the profound heart failure

- the profound liver failure (more than 9 points on

Child-Pugh scale) or an active disease of a liver

- the profound renal failure (clearance of creatinine less than 30

ml/min.), the progressing diseases of kidneys, the confirmed


- the period after performing aortocoronary shunting, a disease

of peripheral arteries, cerebrovascular diseases,

clinically apparent coronary heart disease

- with firmness the remaining values of arterial blood pressure exceeding

140/90 mm Hg in uncontrollable arterial hypertension

- pregnancy, the breastfeeding period

- children's and teenage age up to 16 years

Medicinal interactions

Oral anticoagulants (warfarin)

At the patients receiving warfarin, reception of Arkoksii® in a dose of 120 mg a day was followed by increase approximately for 13% of the International Normalized Relation (INR) of a prothrombin time. At the patients receiving warfarin or similar medicines it is necessary to control MNO indicators during the beginning or change of treatment of Arkoksiey®, in particular in the first few days.

Diuretic drugs, inhibitors of the angiotensin-converting enzyme (ACE)

Are available messages that non-selective NPVP and selection TsOG-2 inhibitors can weaken hypotensive effect of APF inhibitors. This interaction should be taken into account at treatment of the patients accepting Arkoksiya along with APF inhibitors. At patients with renal failures (for example, in dehydration or at advanced age) the similar combination can aggravate functional insufficiency of kidneys.

Arkoksiyu® acetylsalicylic acid it is possible to apply along with acetylsalicylic acid in low doses, intended for prevention of cardiovascular diseases. However co-administration of low doses of acetylsalicylic acid and Arkoksii® can lead to increase in frequency of a canker of a GIT and other complications in comparison with reception of one Arkoksii®. In a dose of 120 mg once a day Arkoksiya® does not influence antithrombocytic activity of acetylsalicylic acid in low doses (81 mg a day). Drug does not replace preventive effect of acetylsalicylic acid in cardiovascular diseases.

Cyclosporine and takrolimus increase risk of development of nephrotoxicity at administration of drug.


there Are data that non-selective NPVP and selection TsOG-2 inhibitors can increase concentration of lithium in plasma. This interaction should be taken into account at treatment of the patients accepting Arkoksiyu® along with lithium.

The methotrexate

At co-administration of Arkoksii® in doses is higher than 90 mg in day and a methotrexate it is necessary to observe possible emergence of toxic effects of a methotrexate.

Oral contraceptives

Reception of Arkoksii® in a dose of 120 mg with the oral contraceptives containing 35 mkg of ethinylestradiol (EE) and from 0.5 to 1 mg of norethindrone within 21 days, at the same time or with a difference increases at 12 o'clock stationary AUC0-24hr for EE by 50-60%. However, concentration of Norethisteronum usually does not increase to clinically significant degree. This increase in concentration of EE should be taken into account when choosing the corresponding oral contraceptive for simultaneous use with Arkoksiey®. The similar fact can lead to increase in frequency of tromboemboliya, due to increase in exposure of EE.

Significant pharmacokinetic interaction with glucocorticosteroids is not revealed.


Etorikoksib does not influence equilibrium AUC0-24ch or elimination of digoxin.

At the same time, etorikoksib increases Cmax (on average by 33%) that can matter at digoxin overdose development.


– the powerful inductor of hepatic metabolism – leads the Concomitant use of Arkoksii® and rifampicin to decrease by 65% of AUC for an etorikoksib in plasma. This interaction should be considered at co-administration of Arkoksii® with rifampicin.

Antacids and ketokonazol (powerful CYP3A4 inhibitor) have no clinically significant effect on pharmacokinetics of Arkoksii®.

The special

instructions Intake of Arkoksii® Medicine demands careful control of arterial blood pressure. All patients when prescribing drug should carry out monitoring of arterial blood pressure within the first two weeks of treatment and periodically further.

Also it is regularly necessary to control indicators of function of a liver and kidneys.

In case of increase in level of hepatic transaminases by 3 times and more, rather upper bound of norm, drug has to be cancelled.

Considering increase of risk of development of undesirable effects with increase in duration of reception, it is necessary to estimate periodically need of continuation of administration of drug and a possibility of a dose decline.

It is not necessary to use drug along with other NPVP.

The cover of the drug Arkoksii® contains lactose in insignificant quantity that should be considered when prescribing drug the patient with a lactose intolerance.

Anamnestic data on development of a canker of a GIT, presence of an infection of Helicobacter pylori, advanced age, long use of NPVP, frequent alcohol intake, heavy somatopathies, dislipidemiya / a lipidemia, diabetes, arterial hypertension, hypostases and a delay of liquid, smoking, clearance of creatinine less than 60 ml/min., the accompanying therapy by the following drugs:

- anticoagulants (for example, warfarin)

- antiagregant (for example, acetylsalicylic acid, klopidogret),

- oral glucocorticosteroids (for example, Prednisolonum),

- selective serotonin reuptake inhibitors (for example, to tsitalopra, fluoxetine, paroksetin, sertraline).

At patients with a liver failure (5-9 points on Child-Pugh scale) are recommended be not to exceeded a daily dose of 60 mg.

Pregnancy and the period of a lactation

Use of drug can negatively affect female fertility and is not recommended to the women planning pregnancy.

The feature of influence of medicine on ability to run

motor transport or moving mechanisms

during treatment needs to be careful during the driving of motor transport and occupation other potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions. Patients at whom episodes of dizzinesses were noted, of drowsiness or weakness, due to refrain from the occupations demanding concentration of attention.


Symptoms: at overdose of drug the emergence of undesirable effects from a GIT is possible, a cardiovascular system and kidneys.

Treatment: symptomatic therapy. The Etorikoksib is not removed at a hemodialysis, removal of drug at peritoneal dialysis was not studied.

Form of release and packing

of the Tablet, film coated 60 mg, 90 mg, 120 mg. On 7 or 14 tablets in blister strip packaging from a film of PVC and aluminum foil. On 1, 2 or 4 packs together with the instruction for medical use in a cardboard pack.

To Store storage conditions at a temperature not above +30 °C.

To store out of children's reach!

3 years

not to apply a period of storage after the expiration date specified on packing.

Prescription status

According to the prescription

the Producer Merck Sharp and B.V. Doum, the Netherlands

the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods)

Representative office 'MSD B.V. East' in Kazakhstan

the Republic of Kazakhstan, 050010,

Almaty, Pr. Dostyk-38,/c Ken-Dala, 5th floor

Ph.: + 7 727 259 80 84

Fax: + 7 727 259 80 90


To develop
Write a review
Related Products
Artoxan (Tenoxicam) 20 mg, 10 film-coated tablets
Polfa (Poland)
EU Anapran 10s 250 mg coated tablets
BioNaturika (Russia)
Artrotsin joint disease during 50 ml cream
Handok Inc. (Korea Republic)
Ketotop 7's transderm patch.
Frosst Iberica, SA (Spain)
Arcoxia® 28's 120 mg film-coated tablets
Out Of Stock
Vetprom (Bulgaria)
Diklopharm 25 mg / ml 3 ml 5's injection